Abstract
Brain lipids contain a high proportion of polyunsaturated fatty acids (PUFA), which are a main component of cell membranes. Omega -3 (ω-3) PUFA eicosapentaeoic acid (EPA) and docosahexaenoic acid (DHA) are the most common PUFA in the brain. The physiological roles of ω-3 PUFA in the brain include regulation of cell membrane fluidity, dopaminergic and serotoninergic transmission, membrane-bound enzymes and cellular signal transduction. They are also thought to play a role in brain glucose metabolism, eicosanoid synthesis, gene expression, cell growth and protection from apoptosis. Increasing evidence from animal and human research shows ω-3 PUFA depletion may play an etiological role in several inflammatory, autoimmune and neuropsychiatric disorders. In particular, an association between ω-3 PUFA and depression was repeatedly suggested in observational and experimental studies on populations affected by major depression, depressed mood or post-partum depression. Consistently, the potential therapeutic role of ω-3 PUFA dietary supplementation was tested in clinical trials on depression. The current review identifies and evaluates available epidemiological evidence of a negative relationship between ω-3 PUFA and depression and examines its biological plausibility. Although current evidence increasingly supports an inverse association between ω-3 PUFA and depression, the validity of findings from observational and experimental research is limited by several methodological issues. Further studies with larger sample sizes and more sophisticated design are required to provide convincing evidence of a causal relationship between ω-3 PUFA and depression.
Keywords: Omega-3 fatty acids, EPA, DHA, polyunsaturated fatty acids, depression
Current Pharmaceutical Design
Title: Omega-3 Polyunsaturated Fatty Acids and Depression: A Review of the Evidence
Volume: 15 Issue: 36
Author(s): R. Liperoti, F. Landi, O. Fusco, R. Bernabei and G. Onder
Affiliation:
Keywords: Omega-3 fatty acids, EPA, DHA, polyunsaturated fatty acids, depression
Abstract: Brain lipids contain a high proportion of polyunsaturated fatty acids (PUFA), which are a main component of cell membranes. Omega -3 (ω-3) PUFA eicosapentaeoic acid (EPA) and docosahexaenoic acid (DHA) are the most common PUFA in the brain. The physiological roles of ω-3 PUFA in the brain include regulation of cell membrane fluidity, dopaminergic and serotoninergic transmission, membrane-bound enzymes and cellular signal transduction. They are also thought to play a role in brain glucose metabolism, eicosanoid synthesis, gene expression, cell growth and protection from apoptosis. Increasing evidence from animal and human research shows ω-3 PUFA depletion may play an etiological role in several inflammatory, autoimmune and neuropsychiatric disorders. In particular, an association between ω-3 PUFA and depression was repeatedly suggested in observational and experimental studies on populations affected by major depression, depressed mood or post-partum depression. Consistently, the potential therapeutic role of ω-3 PUFA dietary supplementation was tested in clinical trials on depression. The current review identifies and evaluates available epidemiological evidence of a negative relationship between ω-3 PUFA and depression and examines its biological plausibility. Although current evidence increasingly supports an inverse association between ω-3 PUFA and depression, the validity of findings from observational and experimental research is limited by several methodological issues. Further studies with larger sample sizes and more sophisticated design are required to provide convincing evidence of a causal relationship between ω-3 PUFA and depression.
Export Options
About this article
Cite this article as:
Liperoti R., Landi F., Fusco O., Bernabei R. and Onder G., Omega-3 Polyunsaturated Fatty Acids and Depression: A Review of the Evidence, Current Pharmaceutical Design 2009; 15 (36) . https://dx.doi.org/10.2174/138161209789909683
DOI https://dx.doi.org/10.2174/138161209789909683 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
Call for Papers in Thematic Issues
Blood-based biomarkers in large-scale screening for neurodegenerative diseases
Disease biomarkers are necessary tools that can be employ in several clinical context of use (COU), ranging from the (early) diagnosis, prognosis, prediction, to monitor of disease state and/or drug efficacy. Regarding neurodegenerative diseases, in particular Alzheimer’s disease (AD), a battery of well-validated biomarkers are available, such as cerebrospinal fluid ...read more
Current Pharmaceutical challenges in the treatment and diagnosis of neurological dysfunctions
Neurological dysfunctions (MND, ALS, MS, PD, AD, HD, ALS, Autism, OCD etc..) present significant challenges in both diagnosis and treatment, often necessitating innovative approaches and therapeutic interventions. This thematic issue aims to explore the current pharmaceutical landscape surrounding neurological disorders, shedding light on the challenges faced by researchers, clinicians, and ...read more
Diabetes mellitus: advances in diagnosis and treatment driving by precision medicine
Diabetes mellitus (DM) is a chronic degenerative metabolic disease with ever increasing prevalence worldwide which is now an epidemic disease affecting 500 million people worldwide. Insufficient insulin secretion from pancreatic β cells unable to maintain blood glucose homeostasis is the main feature of this disease. Multifactorial and complex nature of ...read more
Emerging and re-emerging diseases
Faced with a possible endemic situation of COVID-19, the world has experienced two important phenomena, the emergence of new infectious diseases and/or the resurgence of previously eradicated infectious diseases. Furthermore, the geographic distribution of such diseases has also undergone changes. This context, in turn, may have a strong relationship with ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Pleiotrophin as a Possible New Target for Angiogenesis-Related Diseases and Cancer
Recent Patents on Anti-Cancer Drug Discovery Positive Allosteric Modulators (PAMs) of Metabotropic Glutamate Receptor 5 (mGluR5) Attenuate Microglial Activation
CNS & Neurological Disorders - Drug Targets Metabotropic Glutamate Receptors Modulate Periaqueductal Grey Descending Analgesic System
Central Nervous System Agents in Medicinal Chemistry Natural Compounds Used as Therapies Targeting to Amyotrophic Lateral Sclerosis
Current Pharmaceutical Biotechnology Smart Nanodevices for Point-of-Care Applications
Current Analytical Chemistry Roles of p75NTR in Maintaining Brain Hemostasis and the Implications for p75NTR-targeted Therapies
Current Alzheimer Research The Use of Ghrelin and Ghrelin Receptor Agonists as a Treatment for Animal Models of Disease: Efficacy and Mechanism
Current Pharmaceutical Design PAI-1 as a Target in Kidney Disease
Current Drug Targets A Comprehensive Review on the Medicinal Importance; Biological and Therapeutic Efficacy of <i>Lagenaria siceraria</i> (Mol.) (Bottle Gourd) Standley Fruit
Current Topics in Medicinal Chemistry Pharmacological Perspectives of Wasp Venom
Protein & Peptide Letters Cancer Metastasis: Characterization and Identification of the Behavior of Metastatic Tumor Cells and the Cell Adhesion Molecules, including Carbohydrates
Current Drug Targets - Cardiovascular & Hematological Disorders Aldosterone, Mineralocorticoid Receptor and the Metabolic Syndrome:Role of the Mineralocorticoid Receptor Antagonists
Current Vascular Pharmacology Association of Circulating Cholesterol Level with Cognitive Function and Mild Cognitive Impairment in the Elderly: A Community-based Population Study
Current Alzheimer Research Nucleic Acids Electrotransfer In Vivo: Mechanisms and Practical Aspects
Current Gene Therapy Clinical Management of the Cardiovascular Failure in Sepsis
Current Vascular Pharmacology Melanoma
Current Cancer Therapy Reviews Clinical Molecular Imaging with PET Agents Other than 18F-FDG
Current Pharmaceutical Biotechnology Protein Transduction Domains and their Utility in Gene Therapy
Current Gene Therapy Phenotypic Screening Strategies for Neurodegenerative Diseases: A Pathway to Discover Novel Drug Candidates and Potential Disease Targets or Mechanisms
CNS & Neurological Disorders - Drug Targets Tartaric Acid Enhances Adrenergic Receptor Activity: Test of a General Theory of Extracellular Aminergic GPCR Enhancer Discovery
Current Drug Discovery Technologies